QCG
KYMR icon

Quadrant Capital Group’s Kymera Therapeutics KYMR Stock Holding History

Quadrant Capital Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-80
Closed -$6.66K – 1952
2026
Q1 		$6.66K Buy
+80
New +$6.33K ﹤0.01% 2298

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Quadrant Capital Group's KYMR Position: Q2 2026 in Review

Quadrant Capital Group sold out of Kymera Therapeutics (KYMR) in Q2 2026, closing a stake of 80 shares — an estimated $6.66K sold.

Quadrant Capital Group first reported a position in KYMR in Q1 2026 and held it in 1 quarter. The position peaked at $6.66K in Q1 2026. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Quadrant Capital Group reported no remaining Kymera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 80 Kymera Therapeutics shares in Q2 2026, an estimated $6.66K.
  • Quadrant Capital Group first reported a position in Kymera Therapeutics in Q1 2026 and held it in 1 quarter.
  • Quadrant Capital Group's Kymera Therapeutics position peaked at $6.66K in Q1 2026.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.